PING AN BIOMEDICAL CO-A
PASWNASDAQ🏆 #4045 by market capUS Equity
$647.15▼ $33.98 (−5.25%)
Simulated price1h—
24h▼ 5.3%
7d—
14d—
30d—
1y—
🏦Market Cap
$471,122
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
0.5%
Thin
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
46
Weak
No chart data available for PASW.
Trading Snapshot
- Day Range
- $644.80 – $653.88
- 52-Week Range
- —
- Volume
- $3.46B
- Avg Volume
- $2.70B
- Shares Outstanding
- 24.6M
- Next Earnings
- Oct 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $286,153
- P/E Ratio
- —
- P/S Ratio
- 0.4x
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own PASW
- ✓High-growth profile — revenue up +24.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 59% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$1M▲ +30.3% YoY
Gross Margin (TTM)
58.5%▲ +2.6% YoY
Operating Income (TTM)
$291,346▲ +30.3% YoY
Free Cash Flow (TTM)
$246,176▲ +30.3% YoY
About PING AN BIOMEDICAL CO-A
A company profile for PING AN BIOMEDICAL CO-A isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$757.71
▲ +17.1% Upside
High Target$924.47
Low Target$658.60
Based on 26 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
PING AN BIOMEDICAL CO-A tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift PASW price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
PING AN BIOMEDICAL CO-A announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.